VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
2 hedge funds and large institutions have $780K invested in VALEANT PHARMACEUTICALS INTL in 2013 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
71% less capital invested
Capital invested by funds: $2.7M → $780K (-$1.92M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAA
Peregrine Asset Advisers
Portland,
Oregon
|
-$1.85M |
| 2 |
LWI
Long Wharf Investors
Boston,
Massachusetts
|
-$171K |
VRX Hedge Fund Activity: Q4 2013 in Review
2 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q4 2013, worth a combined $780K — down 71% from $2.7M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Peregrine Asset Advisers, exiting entirely with an estimated $1.85M sold.
- 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q4 2013, down from 3 in Q3 2013.
- Funds reported $780K of VALEANT PHARMACEUTICALS INTL stock for Q4 2013, down 71% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q4 2013 and 1 closed out, a net change of -1 holder.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q4 2013 was Peregrine Asset Advisers, an estimated $1.85M sold.
Based on aggregated 13F filings for Q4 2013.